Telpegfilgrastim injection (PEG-G-CSF) is a sterile, injectable pharmaceutical-grade active pharmaceutical ingredient consisting of recombinant human methionyl granulocyte colony-stimulating factor covalently bound to a methoxypolyethylene glycol chain. The catalog entry “tablet / capsule / granule / injection, oral & injectable” is a master-data classification and should not be read as validation of oral solid dosage forms for this glycoprotein. No WHO-assigned device model number exists for the API; commercial identification is through the manufacturer’s lot-specific code, dossier number, and approved brand presentation. The injectable route is the only clinically and compendially supported route for this molecule.

The molecular design is based on the reference PEG-G-CSF architecture. The protein moiety is a 175-residue recombinant methionyl human G-CSF with a molecular weight of approximately 18.8 kDa. PEGylation with a 20 kDa methoxy polyethylene glycol aldehyde increases the hydrodynamic radius and reduces renal clearance. The nominal commercial presentation for the reference pegfilgrastim injection is 10 mg/mL in a 0.6 mL pre-filled syringe, but the API itself may be supplied as a concentrated liquid intermediate for aseptic filling. Specifications must be established according to ICH Q6B and, where applicable, Ph. Eur. 2208.

The manufacturing process for PEG-G-CSF APIs typically uses recombinant expression in Escherichia coli, inclusion body recovery, oxidative refolding, and N-terminal-specific PEGylation. The PEGylation reaction is conducted under mildly acidic conditions—commonly pH 5.0–6.0—so that the aldehyde-PEG selectively modifies the N-terminal methionine. Unconjugated PEG, reducing agent, and residual reaction salts are removed by diafiltration. A cation-exchange chromatography step then separates mono-PEGylated G-CSF from free protein and higher-order PEGylated species; process experience indicates that the mono-PEGylated fraction should be maintained at ≥90.0%, free protein at ≤5.0%, and high-PEGylated forms at ≤5.0% to avoid altered receptor binding or immunogenicity. Published data for telpegfilgrastim-specific PEGylation stoichiometries may be limited; a complete dossier should include batch analysis from at least three production-scale lots.

Residual free polyethylene glycol is controlled by gel-permeation chromatography or nuclear magnetic resonance spectroscopy; for a 6 mg protein dose, free PEG is typically limited to ≤1.0% of PEGylated species. Residual host-cell DNA is limited to ≤10 ng per therapeutic dose or the lower dossier limit, and host-cell proteins are controlled to ≤100 ppm by a validated ELISA. Endotoxin limits are set for the final injection presentation because downstream filling can introduce pyrogens.

PEG polydispersity index should be controlled; a PDI of ≤1.05 is generally expected for the PEG reagent, with size-exclusion chromatography–multi-angle light scattering confirming conjugate mass distribution. Batch-to-batch variability in PEG reagent molecular weight is a known source of potency and pharmacokinetic variation. For this reason, the PEG supplier is audited to ISO 9001:2015 and the manufacturer maintains a reduced parameter list for PEG lot interchange.

What Prevents a PEG-G-CSF API from Being Formulated as Tablets, Capsules, or Granules?

Three independent barriers exclude the oral route for this molecule. First, gastric fluid at pH <2 and pepsin rapidly denature the protein and cleave the amino acid backbone before it reaches the jejunal brush border. Second, the hydrodynamic radius of a 38–39 kDa PEGylated protein is far above the paracellular transport threshold across intestinal tight junctions, and no saturable carrier for G-CSF is present in the intestinal epithelium. Third, conventional granulation and tableting unit operations—aqueous or aqueous-alcoholic granulation, drying above 40°C, and compression forces typical of rotary tablet presses—can unfold or aggregate the protein. Pharmaceutical test methods such as USP <711> dissolution and USP <701> disintegration are not designed for intact protein APIs and do not predict physiological absorption of a PEG-G-CSF. Published data for telpegfilgrastim-specific oral bioavailability are limited; unmodified recombinant G-CSF has no clinically useful oral activity.

For this reason, the “tablet / capsule / granule” fields in a product listing are catalog attributes only and are not supported by a pharmacopoeial monograph or a regulatory data package. If a solid oral dosage form is requested, the designation should be corrected to injectable-only at the master-data level to prevent downstream medication error.

Specification Panel and Analytical Methods for Pharmacopoeial Release

The release and stability panel for a PEG-G-CSF injectable API integrates compendial general chapters with product-specific assays. Identity is confirmed by liquid chromatography–mass spectrometry peptide mapping; potency is assigned by a cell-proliferation assay using NFS-60 or M-NFS-60 cells calibrated against the WHO international standard. Purity is controlled by reverse-phase HPLC for oxidized and deamidated variants and by size-exclusion HPLC for high-molecular-weight aggregates. Process-related impurities are limited by ELISA for Escherichia coli host-cell proteins, quantitative PCR for residual DNA, and an enzymatic method for residual poly(ethylene glycol).

When a dedicated telpegfilgrastim monograph is not available, the applicant is expected to justify these limits against the reference pegfilgrastim dossier under ICH Q6B and the biosimilar comparability principles of ICH Q5E. Protein concentration is calculated from ultraviolet absorbance at 280 nm using an extinction coefficient verified by amino acid analysis; the value is not inferred from weight-per-millilitre measurements alone. Viral safety is demonstrated through ICH Q5A guidelines, including retrovirus-like particle and in vitro adventitious virus testing of the production cell bank and process validation of virus removal by chromatography and nanofiltration.

Analytical method validation follows ICH Q2(R1). For the potency bioassay, precision at the release limit should be not more than 15% coefficient of variation. Size-exclusion chromatography impurity analysis should be linear from 0.1% to 5.0% of nominal protein concentration. Compendial methods are verified for the specific formulation matrix; non-compendial methods require full validation with specificity, accuracy, precision, linearity, and range.

When Viscosity and Syringe Compatibility Dictate Pre-filled Syringe Design

The injectable formulation at 10 mg/mL is close to Newtonian and low viscosity; however, the fill-finish operation remains surface-sensitive. Pre-filled syringe hardware—typically 1 mL long-staked-needle syringes with 27G needles—can introduce silicone oil from the glass barrel and tungsten from needle insertion. Silicone oil droplets increase subvisible particle counts and can accelerate PEG-G-CSF aggregation. Low-tungsten or tungsten-plug needles, baked-on silicone barrel coatings, and 0.22 µm PVDF or PES sterile filters are specified to control these risks. Transmembrane pressure during filtration is maintained below 1.0 bar to limit shear-induced unfolding. Fill volume for a nominal 0.6 mL dose is controlled to 0.600 mL ± 0.030 mL, with 100% in-process weight verification on rotary piston or peristaltic fill lines.

Storage is specified at 2–8°C and protected from light. Freezing must be avoided because ice–water interfaces damage the PEG layer and promote aggregation. In-use data for the reference product support limited room-temperature exposure of 48 h; telpegfilgrastim-specific in-use stability must be generated under the approved protocol. The liquid formulation is incompatible with strong oxidizing agents, strong reducing agents, and prolonged exposure to shear rates above the linear flow range of the filling system. No compound-specific oral solid dosage form has been developed; attempts to dry the API in a granular matrix would require a full formulation feasibility study under ICH Q8.

Compared with unPEGylated filgrastim, PEG-G-CSF has a longer half-life because the increased hydrodynamic radius reduces glomerular filtration. Reference pegfilgrastim is administered as a single subcutaneous dose of 6 mg per chemotherapy cycle, whereas filgrastim is used at 5 µg/kg daily until neutrophil recovery. The two products are not interchangeable on a milligram basis. Differentiation from other long-acting G-CSF products—such as lipegfilgrastim or balugrastim—may involve PEG chain length, PEG attachment site, glycosylation, or sustained-release formulation. For biosimilar telpegfilgrastim, equivalence is established through comparative pharmacokinetic and pharmacodynamic studies using absolute neutrophil count area under the curve and duration of severe neutropenia, not by in vitro potency alone.

Clinical use is limited to approved supportive care under hematology/oncology protocols: reduction of duration of severe neutropenia and incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy, and peripheral blood stem cell mobilisation where authorized. The injection is given subcutaneously; intravenous administration is not the licensed route for reference pegfilgrastim. Patients with known hypersensitivity to G-CSF, PEG, or Escherichia coli-derived proteins require exclusion. The product is contraindicated in the presence of visible particles outside USP <790> acceptance criteria. Administration should be withheld if the syringe shows cracks, discoloration, or aggregate formation on visual inspection.

Supply chain handling is controlled under ICH Q7 and aseptic manufacturing in Grade A/ISO 5 zones. Temperature-controlled shipping at 2–8°C with calibrated data loggers is required, and the receiving site should verify pH according to Ph. Eur. 2.2.6 and osmolality. The API is held in quarantine until identity, endotoxin, and potency release results are complete. The catalog designation “Pharma Grade API” indicates routine GMP manufacturing and sterile processing, not oral suitability. If the master-data fields for tablet, capsule, or granule are retained in a purchasing system, regulatory affairs should confirm that the approved dosage form is injection only.